Table 2.
Group differences in illness duration, healthcare utilization, and treatment data (mean and standard deviation or number and percentage, followed by overall sample size).
| ARFID | GI-related SSRD | Difference between ARFID and GI-related SSRD | |
|---|---|---|---|
| Clinic initially referred to | Fisher’s = 55.876, p < .001*** b | ||
| Adolescent Medicine | 4 (6.5%), 62 | 1 (2.7%), 37 | |
| Consultation-Liaison Psychiatry | 4 (6.5%), 62 | 26 (70.3%), 37 | |
| Eating Disorders | 40 (64.5%), 62 | 3 (8.1%), 37 | |
| Gastroenterology | 7 (11.3%), 62 | 3 (8.1%), 37 | |
| Medical Psychology | 0 (0%), 62 | 1 (2.7%), 37 | |
| Mind-Body Connection Program/Outpatient Mental Health Teaching Clinic a | 1 (1.6%), 62 | 2 (5.4%), 37 | |
| Other medical/psychiatric subspecialty clinics | 6 (9.7%), 62 | 1 (2.7%), 37 | |
| Pre-assessment illness duration (years) | 2.02 (2.77), 59 | 1.42 (1.80), 35 | t(92) = 1.148, p =.254 95% CI [−.18,.66], d = .24 |
| Pharmacological medication at time of assessment | 26 (41.9%), 62 | 16 (43.2%), 37 | χ2(1, N = 99) = .016, p = .899 |
| Antidepressant | 20 (32.3%) | 16 (43.2%) | |
| Antipsychotic | 5 (8.1%) | 4 (10.8%) | |
| Anxiolytic | 6 (9.7%) | 1 (2.7%) | |
| Stimulant | 2 (3.2%) | 0 (0%) | |
| Other (e.g., anticonvulsant) | 0 (0%) | 3 (8.1%) | |
| Services accessed prior to assessment (includes past and current) | |||
| Outpatient services | |||
| Mental health c | 40 (64.5%), 62 | 22 (59.5%), 37 | χ2(1, N = 99) = .253, p = .615 |
| Physical health (e.g., medical subspecialty clinic) c | 37 (59.7%), 62 | 25 (67.9%), 37 | χ2(1, N = 99) = .616, p = .432 |
| Community hospital inpatient services | |||
| Mental Health Unit c | 4 (6.5%), 62 | 2 (5.4%), 37 | p = 1.000b |
| Medical Unit c | 12 (19.4%), 62 | 7 (18.9%), 37 | χ2(1, N = 99) = .003, p = .958 |
| Tertiary inpatient services | |||
| Mental Health Unit c | 4 (6.5%), 62 | 4 (10.8%), 37 | p = .467 b |
| Medical Unit c | 12 (19.4%), 62 | 10 (27.0%), 37 | χ2(1, N = 99) = .789, p = .374 |
| Specialized services for ARFID or SSRD c | 5 (8.1%), 62 | 3 (8.1%), 37 | p = 1.000 b |
Note. ARFID = Avoidant-Restrictive Food Intake Disorder; GI = gastrointestinal; SSRD = Somatic Symptom and Related Disorder. Data related to residential and day treatment for eating disorders were extracted, but not included as no participants accessed these services. Participants were also reported to have accessed “other” services, such as the emergency department and alternative medicine practitioners.
*p < .05; **p < .01; ***p < .001; analyses that were significant are bolded.
aMind-Body Connection Program is a group treatment for youth with somatization and their families.
bFisher’s exact test (2-sided) used as the assumption of expected frequencies was violated.
cEvaluated against a Bonferroni-adjusted p < .007.